Table 2.

The rank of median overall survival of recurrent GBM after oncolytic treatments

Year	Generic name	No.	mKPS	mAge	Administration	Max-dose	mOS	minOS	maxOS
2022	G47Δ	19	80	51	I.T	1 × 109 PFU	20.2	4.2	65.3
2023	DNX-2401	49	90	53	I.T+ pembrolizumab	5 × 1010 VP	12.5	2.8	41.6
2018	PVSRIPO	61	90	55	I.T CED	7 × 109 PFU	11.4	3.1	70.4
2017	ParvOryx	18	90	58.5	I.T-excision-I.C/I.V-excision-I.C	5 × 109 PFU	11.2	3.2	40.9
2021	G207	10	–	12.5	I.T + RT	1 × 108 PFU+5 Gy	10.7	3.8	19.4
2018	DNX-2401	33	90	52	I.T/I.T-excision- I.C	3 × 1010 VP	9.8	2.3	57.9
2006	NDV-HUJ	11	80	51	I.V.	5.5 × 1010 EID50	8	0.75	16.5
2000	HSV1716	8	60	52.5	I.T	1 × 105 PFU	7.5	2	24
2004	HSV1716	4	90	50.5	I.C	1 × 105 PFU	7.5	3	22
2022	G47Δ	13	90	45	I.T	1 × 109 PFU	7.2	3.2	143.9
2009	G207	6	75	54.6	I.T	1.15 × 109 PFU	6.6	2	20.75
2000	G207	16	–	56.5	I.T	3 × 109 PFU	6	2	17
2002	HSV1716	11	80	49	I.T-excision	1 × 105 PFU	6	1	13
2004	ONYX- 015	17	90	55	I.C	1 × 1010 PFU	5	1.2	23.4
2014	Reovirus	15	90	51.52	I.T CED	1 × 1010 PFU	4.6	3.2	32.9
2022	DNX-2401	19	90	54	I.T CED	3 × 1010 PFU	4.3	2.3	93.1
2014	G207	7	90	55	I.T+RT	1.0 × 109 PFU	4.15	1.5	12.8
2008	Reovirus	9	–	–	I.T-excision	7 × 108 PFU	3.25	1.5	15.85